An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer

NCT07271446 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

8

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

BIOLOGICAL: PB101 plus EGFR-TKI including gefitinib, erlotinib, afatinib, or osimertinib

Sponsor

Precision Biotech Taiwan Corp.